Skip to main content

Table 3 Responses to ICI treatment according to the risk groups

From: A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

Best response to ICI

All

Low-risk

n = 76

n (%)

High-risk

n = 33

n (%)

P value

 

n = 109

Low vs.

n (%)

high risk

Complete response

10 (9.2%)

9 (11.8%)

1 (3.0%)

 

Partial response

41 (37.6%)

32 (42.1%)

9 (27.3%)

 

Stable disease

20 (18.3%)

16 (21.1%)

4 (12.1%)

 

Progressive disease

37 (33.9%)

19 (25.0%)

18 (54.5%)

 

Not evaluable

1 (0.9%)

0 (0%)

1 (3.0%)

0.012*

  1. ICI, immune checkpoint inhibitor: *p < 0.05